{"database": "openregs", "table": "documents", "rows": [["FDA-2023-N-0061-0044", "FDA", "FDA-2023-N-0061", "Memorandum - Drug Products or Categories of Drug Products That Present Demonstrable Difficulties for Compounding Under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act (Proposed Rule)", "Other", "Memorandum", "2024-11-06T05:00:00Z", 2024, 11, "2024-11-06T05:00:00Z", null, "2024-11-06T17:00:18Z", null, 0, 0, "09000064867ffe78"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2023-N-0061-0044"], "units": {}, "query_ms": 92.58489101193845, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}